![Leif Niclas Fredrik Löwgren](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Leif Niclas Fredrik Löwgren
Direttore/Membro del Consiglio presso Omnivation AB
Profilo
Leif Niclas Fredrik Löwgren is currently a Director at Omnivation AB.
He was previously a Director at Copperstone Resources AB, QuiaPEG Pharmaceuticals AB, NextCell Pharma AB, and Quiapeg Pharmaceuticals Holding AB.
Mr. Löwgren holds an MBA from the University of Stockholm.
Posizioni attive di Leif Niclas Fredrik Löwgren
Società | Posizione | Inizio |
---|---|---|
Omnivation AB | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Leif Niclas Fredrik Löwgren
Società | Posizione | Fine |
---|---|---|
GRUVAKTIEBOLAGET VISCARIA | Direttore/Membro del Consiglio | 14/05/2019 |
NEXTCELL PHARMA AB | Direttore/Membro del Consiglio | - |
QUIAPEG PHARMACEUTICALS HOLDING AB | Direttore/Membro del Consiglio | - |
QuiaPEG Pharmaceuticals AB
![]() QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | - |
Formazione di Leif Niclas Fredrik Löwgren
University of Stockholm | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
GRUVAKTIEBOLAGET VISCARIA | Non-Energy Minerals |
NEXTCELL PHARMA AB | Health Technology |
QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
Aziende private | 2 |
---|---|
QuiaPEG Pharmaceuticals AB
![]() QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
Omnivation AB |
- Borsa valori
- Insiders
- Leif Niclas Fredrik Löwgren